Cargando…

Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years

Models of skin diseases, such as psoriasis and scleroderma, must accurately recapitulate the complex microenvironment of human skin to provide an efficacious platform for investigation of skin diseases. Skin disease research has been shifting from less complex and less relevant 2D (two-dimensional)...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanton, Diana Nicole, Ganguli-Indra, Gitali, Indra, Arup Kumar, Karande, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877988/
https://www.ncbi.nlm.nih.gov/pubmed/35214050
http://dx.doi.org/10.3390/pharmaceutics14020319
_version_ 1784658546386796544
author Stanton, Diana Nicole
Ganguli-Indra, Gitali
Indra, Arup Kumar
Karande, Pankaj
author_facet Stanton, Diana Nicole
Ganguli-Indra, Gitali
Indra, Arup Kumar
Karande, Pankaj
author_sort Stanton, Diana Nicole
collection PubMed
description Models of skin diseases, such as psoriasis and scleroderma, must accurately recapitulate the complex microenvironment of human skin to provide an efficacious platform for investigation of skin diseases. Skin disease research has been shifting from less complex and less relevant 2D (two-dimensional) models to significantly more relevant 3D (three-dimensional) models. Three-dimensional modeling systems are better able to recapitulate the complex cell–cell and cell–matrix interactions that occur in vivo within skin. Three-dimensional human skin equivalents (HSEs) have emerged as an advantageous tool for the study of skin disease in vitro. These 3D HSEs can be highly complex, containing both epidermal and dermal compartments with integrated adnexal structures. The addition of adnexal structures to 3D HSEs has allowed researchers to gain more insight into the complex pathology of various hereditary and acquired skin diseases. One method of constructing 3D HSEs, 3D bioprinting, has emerged as a versatile and useful tool for generating highly complex HSEs. The development of commercially available 3D bioprinters has allowed researchers to create highly reproducible 3D HSEs with precise integration of multiple adnexal structures. While the field of bioengineered models for study of skin disease has made tremendous progress in the last decade, there are still significant efforts necessary to create truly biomimetic skin disease models. In future studies utilizing 3D HSEs, emphasis must be placed on integrating all adnexal structures relevant to the skin disease under investigation. Thorough investigation of the intricate pathology of skin diseases and the development of effective treatments requires use of highly efficacious models of skin diseases.
format Online
Article
Text
id pubmed-8877988
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88779882022-02-26 Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years Stanton, Diana Nicole Ganguli-Indra, Gitali Indra, Arup Kumar Karande, Pankaj Pharmaceutics Review Models of skin diseases, such as psoriasis and scleroderma, must accurately recapitulate the complex microenvironment of human skin to provide an efficacious platform for investigation of skin diseases. Skin disease research has been shifting from less complex and less relevant 2D (two-dimensional) models to significantly more relevant 3D (three-dimensional) models. Three-dimensional modeling systems are better able to recapitulate the complex cell–cell and cell–matrix interactions that occur in vivo within skin. Three-dimensional human skin equivalents (HSEs) have emerged as an advantageous tool for the study of skin disease in vitro. These 3D HSEs can be highly complex, containing both epidermal and dermal compartments with integrated adnexal structures. The addition of adnexal structures to 3D HSEs has allowed researchers to gain more insight into the complex pathology of various hereditary and acquired skin diseases. One method of constructing 3D HSEs, 3D bioprinting, has emerged as a versatile and useful tool for generating highly complex HSEs. The development of commercially available 3D bioprinters has allowed researchers to create highly reproducible 3D HSEs with precise integration of multiple adnexal structures. While the field of bioengineered models for study of skin disease has made tremendous progress in the last decade, there are still significant efforts necessary to create truly biomimetic skin disease models. In future studies utilizing 3D HSEs, emphasis must be placed on integrating all adnexal structures relevant to the skin disease under investigation. Thorough investigation of the intricate pathology of skin diseases and the development of effective treatments requires use of highly efficacious models of skin diseases. MDPI 2022-01-28 /pmc/articles/PMC8877988/ /pubmed/35214050 http://dx.doi.org/10.3390/pharmaceutics14020319 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stanton, Diana Nicole
Ganguli-Indra, Gitali
Indra, Arup Kumar
Karande, Pankaj
Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title_full Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title_fullStr Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title_full_unstemmed Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title_short Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
title_sort bioengineered efficacy models of skin disease: advances in the last 10 years
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877988/
https://www.ncbi.nlm.nih.gov/pubmed/35214050
http://dx.doi.org/10.3390/pharmaceutics14020319
work_keys_str_mv AT stantondiananicole bioengineeredefficacymodelsofskindiseaseadvancesinthelast10years
AT ganguliindragitali bioengineeredefficacymodelsofskindiseaseadvancesinthelast10years
AT indraarupkumar bioengineeredefficacymodelsofskindiseaseadvancesinthelast10years
AT karandepankaj bioengineeredefficacymodelsofskindiseaseadvancesinthelast10years